BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

BBIONYSE / NASDAQHealthcareSmall cap

$76.03-$2.15 (-2.8%)

Last close · Data as of Nov 20, 2026

Market cap
$13.2B
P/E
-18.2x
EV / EBITDA
-26.4x
Revenue
$502.1M
Net margin
-144.4%
ROCE
-77.5%

+17.7% over the last year

BridgeBio Pharma, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+12.6%
3M
-8.3%
6M
+11.4%
1Y
+17.7%
5Y
Hidden
  • This period includes a one-day price step on 27 Dec 2021 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$2.15 (-2.8%) from $78 to $76 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BBIO, bought on each weekday since 2021.

News & filings

What BridgeBio Pharma filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.

Read moreShow less

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Sector
Healthcare
Shares outstanding
194.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$13.2B
P/E
-18.2x
P/B
-6.3x
EV / EBITDA
-26.4x
EV / Sales
28.8x
P/S
26.3x
52-week high
$90.17
52-week low
$63.30

Profitability

Operating margin
-100.0%
Net margin
-144.4%
EBITDA margin
-109.3%
ROE
34.7%
ROCE
-77.5%
ROA
-77.4%
Asset turnover
0.54

Growth

Revenue
$502.1M
Revenue growth, 1Y
126.3%
Revenue CAGR, 3Y
86.3%
Net profit growth, 1Y
35.3%
Free cash flow
-$455.5M

Solvency

Current ratio
2.77
Debt / Equity
-0.89
Debt / Assets
1.99
CFO / Net profit
0.62
Cash / Market cap
4.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$502.1M
Cost of revenue$21.0M
Gross profit$481.1M
Operating expenses$983.2M
Research and development$451.9M
Selling, general and administrative$531.2M
Operating income-$502.1M
Interest and other-$230.4M
Pretax income-$732.5M
Tax and other-$7.6M
Net income-$724.9M

Revenue and net profit

Revenue grew 126.3% in FY2025; net profit is the dashed line.

BridgeBio Pharma, Inc. revenue and net profit by fiscal year
BridgeBio Pharma, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$77.6M-$481.2M
FY2023$9.3M-$643.2M
FY2024$221.9M-$535.8M
FY2025$502.1M-$724.9M

Cash flows

FY2025: -$445.9M from operations, -$455.5M free after investment (dashed).

BridgeBio Pharma, Inc. operating and free cash flow by fiscal year
BridgeBio Pharma, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$419.5M-$425.8M
FY2023-$527.7M-$529.0M
FY2024-$520.7M-$529.6M
FY2025-$445.9M-$455.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$502.1M+126.3%1Y
EBITDA
-$548.8M
Net profit
-$724.9M
Cash from operations
-$445.9M
Free cash flow
-$455.5M
Revenue CAGR, 3Y
86.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$502.1M-$548.8M-$724.9M-$455.5M34.7%+126.3%+35.3%

Monthly returns

Month-by-month returns of BBIO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$936.0M
Liabilities$3.0B
Equity-$2.1B
Paid-in capital$2.1B
Retained earnings-$3.8B
Treasury stock$323.3M
Minority interest$10.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BBIO highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. BridgeBio Pharma, Inc. (this company)28.8x

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
BridgeBio Pharma, Inc.BBIOthis company$13.2B-18.2x-6.3x34.7%-26.4x
Guardant Health, Inc.GH$17.6B-42.4x-177.7x419.2%-50.7x
Axsome Therapeutics, Inc.AXSM$11.9B-65.0x134.9x-207.5%-70.2x
Madrigal Pharmaceuticals, Inc.MDGL$11.4B-39.4x18.9x-47.8%-43.5x
Arrowhead Pharmaceuticals, Inc.ARWR$10.6B-6491.0x22.7x-0.3%65.9x
Cytokinetics, IncorporatedCYTK$9.8B——119.0%—
The Ensign Group, Inc.ENSG$9.6B27.9x4.3x15.4%19.9x
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
Peer median—-39.4x5.9x7.5%-39.8x

Year-to-date ROI

BBIO since 1 January, against earlier years.

Historical volatility

BBIO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

BridgeBio Pharma, Inc. operating margin by fiscal year
BridgeBio Pharma, Inc. operating margin by fiscal year
DateOperating margin
FY2022-603.3%
FY2023-6445.6%
FY2024-260.2%
FY2025-100.0%
LineFY2025
Cost of revenueCost Of Revenue$21.0M
Gross profitGross Profit$481.1M
Operating expensesOperating Expense$983.2M
Research and developmentResearch And Development$451.9M
Selling, general and administrativeSelling General And Administration$531.2M
Total expensesTotal Expenses$1.0B
Pretax incomePretax Income-$732.5M

Learn while you research

Academy chapters picked for BridgeBio Pharma, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing126% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →